The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to hit the market and disrupt the medical sector. These treatments are ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

GLP-1 medications are drugs that mimic the effects of the GLP-1 hormone, helping regulate blood sugar and reduce appetite. They are primarily used for managing type 2 diabetes but are also ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes and more recently for obesity and other labeled ...

On October 2, 2024, the U.S. Food and Drug Administration (FDA) determined the shortage of the tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been “resolved”.

Nobody could have predicted the vogue for GLP-1 drugs to promote weight loss. In the US alone, the number of patients starting GLP-1 treatments for nondiabetic purposes has increased by 700% since ...

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, an injection used to control blood sugar levels of type 2 diabetics, but it’s also approved for weight loss for use in ...

Learn about GLP-1 medications, their benefits, risks and who should (or shouldn’t) consider using them. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 ...